| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We aimed to image malignant tumors by 2 radiotherapy sessions In the first session, we injected CT-detectable microcapsules with P-selectin to observe malignant tumors by VEGFR-1/2 and αvβ3antibody-antigen complex accumulation. In the second session, we performed chemo-radiotherapy using microcapsules which have a high affinity for P-selectin and PSGL-1.
In the first session, anti-VEGFR-1/2 and anti-αvβ3microcapsules accumulated in the malignant tumor, which could be detected by CT. These microcapsules released P-selectin and PSGL-1 in response to the first irradiation. Subsequently, microcapsules for tumor treatment were injected. Those microcapsules accumulated around the tumor through P-selectin-antigen-antibody reaction. In the second session, microcapsules released carboplatin. The released carboplatin attacked synertistically with radiation, which resulted in increased antitumor effect. And localization of carboplatin by capsules reduced adverse effect.
|
